

Press release

Indegene Reports 4.9% QoQ Growth in Revenue, with a healthy PAT margin of 15.6%

Bengaluru, India, April 28, 2025: Indegene, a digital-first, life sciences commercialization company, announced financial results for the quarter and the full year ended March 31, 2025.

- Achieved revenue of INR 7,556 million in Q4FY25, a growth of 4.9% QoQ
- Achieved PAT of INR 1,176 million in Q4FY25, a growth of 7.2% QoQ
- Full-year revenue of INR 28,393 million in FY25, a growth of 9.6% YoY
- Full-year PAT of INR 4,067 million in FY25, a growth of 20.8% YoY
- Announced its first-ever dividend at 100% for FY25

Sl. No.	Particulars	Quarter ended			Year ended	
		Mar 31, 2025	Dec 31, 2024	Mar 31, 2024	Mar 31, 2025	Mar 31, 2024
1.	Revenue from operations	7,556	7,204	6,730	28,393	25,896
2.	Revenue from operations (\$ Mn)	87.4	85.2	81.1	335.7	312.8
3.	YoY revenue growth from operations (%)	12.3%	7.0%	6.5%	9.6%	12.3%
4.	EBITDA	1,526	1,501	1,474	5,622	5,356
5.	EBITDA margin (%)	20.2%	20.8%	21.9%	19.8%	20.7%
6.	Profit after tax	1,176	1,097	948	4,067	3,367
7.	Profit margin (%)	15.6%	15.2%	14.1%	14.3%	13.0%

Indegene was recognized as a Front-runner in GenAI for Life Sciences by the Everest Group. The company featured in Financial Times' High Growth Companies Asia-Pacific 2025, and Great Place To Work's Top 50 India's Best Workplaces in Health & Wellness.

"We sustained our profitable growth momentum in Q4FY25, clocking revenue growth of 4.9% QoQ, buoyed by recent deal wins from the last 2 quarters. We continued the momentum on deal wins this quarter also, which positions us well to drive continued revenue growth in FY26", said Manish Gupta, Chairman and CEO, Indegene Limited. "We remain focused on expanding our client base even as we continue to drive growth from existing and newly added clients. On the technology front, we further strengthened our capabilities with the launch of Cortex - our flagship GenAI platform, purpose-built for the life sciences industry. We have also announced our maiden dividend at 100% for FY25."

"Q4FY25 rounded out another year of stable and profitable growth. We delivered the highest-ever PAT margin of 15.6% for the quarter. The full-year PAT crossed INR 400 crs, a growth of 20.8% YoY", said Suhas Prabhu, CFO, Indegene Limited. "We will continue to focus on strong execution, margin improvement and greater value creation for our clients in FY26 to accelerate our growth goals."



About Indegene

Indegene is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It's what drives Indegene's team and their purpose to enable healthcare organizations to be future-ready. To learn more, please visit www.indegene.com

For Investor inquiries, please contact:
IR@Indegene.com

For media inquiries, please contact:
Yadunandan K V | yadunandan.kv@indegene.com